News >

Frontline Durvalumab Plus Tremelimumab Falls Short in Phase III NSCLC Trial

Jason Harris
Published: Thursday, Jul 27, 2017

Sean Bohen, MD, PhD

Sean Bohen, MD, PhD
Frontline durvalumab (Imfinzi), either in combination with tremelimumab or as a single agent, did not improve progression-free survival (PFS) in patients with stage IV metastatic non–small cell lung cancer (NSCLC) compared with standard platinum-based chemotherapy.

In the study, the level of response increased with higher levels of PD-L1 expression. The highest overall response rate (ORR) of 30.9% (95% CI, 20.2-43.3) occurred in patients with PD-L1 expression on ≥90% of tumor cells. ORR was 16.4% (95% CI, 10.8-23.5) in patients with PD-L1 expression ≥25%, and 7.5% (95% CI, 3.1-14.5) in patients with PD-L1 expression levels <25%.
Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016 Mar;17(3):299-308.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication